Amgen Inc. (AMGN)
After hours:
| Previous close | 276.38 |
| Open | 276.04 |
| Bid | 273.90 x 100 |
| Ask | 274.19 x 100 |
| Day's range | 272.35 - 276.11 |
| 52-week range | 211.71 - 329.72 |
| Volume | |
| Avg. volume | 2,926,600 |
| Market cap | 148.141B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | 21.92 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 9.00 (3.28%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- PR Newswire
AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
- PR Newswire
AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia
- PR Newswire
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT.
